FDA expands use of Pfizer's best-selling pneumonia vaccine

July 12, 2016 8:52 PM

18 0

FDA expands use of Pfizer's best-selling pneumonia vaccine

Pfizer Inc said on Tuesday the U.S. Food and Drug Administration had expanded the use of its best-selling pneumonia vaccine, Prevnar, to adults aged 18 through 49.

The vaccine, which is already approved for use in adults aged 50 and above, and children aged 6 weeks to 17 years, prevents invasive diseases caused by 13 Streptococcus pneumoniae strains.

Read more

To category page

Loading...